Auto-Injected Testosterone May Address Some TRT Shortcomings
Single-dose disposable auto injector approved for once-weekly subcutaneous administration of testosterone may cut down on potential problems associated with other options.
Single-dose disposable auto injector approved for once-weekly subcutaneous administration of testosterone may cut down on potential problems associated with other options.
In a recent meta-analysis, testosterone therapy was not associated with major or minor adverse cardiovascular events.
In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events.
Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.
From 2013 to 2016, the relative decrease in testosterone prescriptions was 48% among established testosterone users and 62% among new users.
Among men aged 20-39 years, those in the top quartile of sugar-sweetened beverage intake had 2.3-fold greater odds of low testosterone than those in the bottom quartile.
Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.
Findings from the largest study to date examining the effect of TRT in prostate cancer patients build on previous evidence showing that the treatment does not affect disease progression risk.
Researchers find a higher incidence of clinically diagnosed urinary stones among men receiving testosterone replacement therapy (TRT) vs matched controls not on TRT.